 |
MR Vol.12 No.4 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.12 No.4 |
 |
|
|
 |
|
|
Cyclosporin A therapy for interstitial pneumonitis
associated with rheumatic disease |
|
|
| Y. Tokano1, H. Ogasawara1, S. Ando1, T.
Fujii1, H. Kaneko1, N. Tamura1, T. Yano1, K. Hirokawa1,
T. Fukazawa1, A. Murashima1, S. Kobayashi1, I. Sekigawa1,
Y. Takasaki1, N. Iida1, H. Hashimoto1 |
(1) Department of Rheumatology and Internal
Medicine, Juntendo University, School of Medicine, 2-1-1 Hongo,
Bunkyo-ku, Tokyo 113-8421, Japan
|
| |
| Abstract |
| Abstract To determine the efficacy of cyclosporin
A (CysA) for the treatment of steroid-resistant interstitial pneumonitis
(IP), we enrolled 25 patients with various rheumatic diseases and
steroid-resistant IP in a pilot study [4 patients with rheumatoid
arthritis (RA), 2 with systemic lupus erythematosus (SLE), 11 with
polymyositis/dermatomyositis (PM/DM), 4 with systemic sclerosis
(SSc), 1 with mixed connective tissue disease (MCTD), 3 with Sjogren
syndrome (SS)]. Twelve patients (48%) showed a persistent response
to CysA therapy, and 7 of them had PM/DM, including so-called amyopathic
DM. Patients with a persistent response had moderately elevated
lactate dehydroxygenase (LDH) levels, whereas patients who died
had much higher LDH levels and hypoxia. Even patients with low
blood levels of CysA achieved a persistent response. In responding
patients, the symptoms, chest X-ray findings, arterial oxygen tension,
and LDH level all improved after less than 4 weeks. In conclusion,
CysA seem to be useful for treating patients with steroid-resistant
IP, whose duration is short and severity is mild. |
| |
| Key words |
| Key words Cyclosporin A ・ Interstitial pneumonitis
(IP) ・ Polymyositis/dermatomyositis (PM/DM) ・ Systemic sclerosis
(SSc) |
|
|
 |
|
|
